Official Press Conference Programme

• (Chair) Sharon Lewin, IAS President-Elect (Australia)
• Núria Climent, Hospital Clinic-IDIBAPS/ University of Barcelona (Spain)
  Exceptional post-treatment control associated with strong NK and ϒɗ cytotoxic T-cells
• Jana Dickter, City of Hope (USA)
  The “City of Hope” Patient: Prolonged HIV-1 remission without antiretrovirals (ART) after allogeneic hematopoietic stem cell transplantation (aHCT) of CCR5-Δ32/Δ32 donor cells for acute myelogenous leukemia (AML)
• Annie Luetkemeyer, Zuckerberg San Francisco General Hospital, UCSF (USA)
  Doxycycline post-exposure prophylaxis for STI prevention among MSM and Transgender Women on HIV PrEP or living with HIV: High efficacy to reduce incident STI’s in a randomized trial
• Eli Boritz, Vaccine Research Center, NIAID (USA)
  Transcriptional programs of HIV silencing and cell survival in HIV-infected memory CD4 T cells under antiretroviral therapy
• Madisa Mine, Botswana Ministry of Health and Wellness (Botswana)
  Botswana achieved the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets: Results from the Fifth Botswana HIV/AIDS Impact Survey (BAIS V), 2021
• Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS Research Centre (Thailand)
  Week 48 Results of a Phase 3 Randomized Controlled Trial of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) vs Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate (DTG+F/TDF) as Initial Treatment in HIV/HBV-Coinfected Adults (ALLIANCE)

• Adeeba Kamarulzaman, University of Malaya (Malaysia)
• Winnie Byanyima, UNAIDS (Switzerland)
• Anthony Fauci, National Institute of Allergy and Infectious Diseases (NIAID)
• John Nkengasong, U.S. Global AIDS Coordinator and Special Representative For Health Diplomacy (USA)
• Andriy Klepikov, Alliance for Public Health (Ukraine)
• Anita Vandenbeld MP, Parliamentary Secretary to the Minister of International Development (Canada)
• Keren Dunaway, International Community of Women Living with HIV (Argentina)

• (Chair) Adeeba Kamarulzaman, IAS President and AIDS 2022 International Co-Chair (Malaysia)
• Sinead Delany-Moretlwe, University of the Witwatersrand (South Africa)
  Long acting cabotegravir: updated efficacy and safety results from HPTN 084
• Beatriz Grinsztejn, Evandro Chagas National Institute of Infectious Diseases – Fiocruz (Brazil)
  Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions with Long-acting Cabotegravir (CAB-LA)
• Meg Doherty, World Health Organization (Switzerland)
  Launch of WHO CAB-LA Guidelines
• Charles Gore, Medicines Patent Pool (Switzerland)
  Deborah Waterhouse, ViiV Healthcare (USA)
  Update on ViiV Healthcare and Medicine Patent Pool negotiations on CAB-LA for PrEP in Low- and Middle-Income Countries
• Tenu Avafia, Unitaid (Switzerland)
  New Plans and Partnerships to Speed Equitable Access to Longer-acting HIV Prevention Products

• (Chair) Adeeba Kamarulzaman, IAS President and AIDS 2022 International Co-Chair (Malaysia)
• Ambassador John N. Nkengasong, U.S. Global AIDS Coordinator and Special Representative for Health Diplomacy (USA)
• Winnie Byanyima, UNAIDS (Switzerland)
• Maurine Murenga, Executive Director of Lean on Me Foundation and Coordinator, TB Women Global (Kenya)
  Update on the revolutionary global U=U movement

Find out more here.